**Supplemental Table S3. Interval between last prior chemotherapy and first dose of study treatment**

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **Time (Months)** | **Spartalizumab 400 mg Q4W (*N* = 82)** | **Chemotherapya (*N* = 40)** | **Crossover to Spartalizumab 400 mg Q4W (*N* = 25)** | **All Spartalizumab**  **(*N* = 107)** |
| **Mean (SD)** | 5.8 (7.7) | 6.0 (8.2) | 4.4 (4.9) | 5.5 (7.2) |
| **Median** | 2.3 | 2.8 | 2.7 | 2.4 |
| **Min–max interval** | 0.03–36.1 | 0.7–41.6 | 0.7–18.6 | 0.03–36.1 |
| Q4W, every 4 weeks; SD, standard deviation. a Per investigator's choice. | | | | |